What you'll get out of this episode:

• PDS Biotechnology targets the key limitations of CAR T and cancer vaccine therapies using lipid nanoparticle-based immunotherapy.
• Their lead candidate, PDS0101, demonstrated over 2x improvement in survival for HPV-positive head and neck cancer.
• The platform technology shows consistent efficacy across multiple independent Phase 2 trials.
• Late-stage clinical programs focus on HPV16+ head and neck cancer, with additional trials for colorectal, prostate, and MUC1+ cancers.

To Learn More About Our Guest And Their Company:
Guest LinkedIn https://www.linkedin.com/in/frank-bedu-addo-4797947/
Company LinkedIn https://www.linkedin.com/company/pds-biotechnology-corporation/
Website https://www.pdsbiotech.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Aspargo tackles inefficiencies in pill-based drug delivery through innovative oral suspensions.
• The company’s patented technology improves absorption via buccal and GI routes.
• First commercial product, HisQ (oral spray sildenafil), delivers rapid ED treatment in just 10 minutes—even on a full stomach.
• Future products include sprays for weight loss and hair loss, launching via a telehealth platform.
• Upcoming smart dispenser connects with physicians and caregivers for enhanced adherence and monitoring.

To Learn More About Our Guest And Their Company:
Guest LinkedIn https://www.linkedin.com/in/michael-demurjian-02868113/
Company LinkedIn https://www.linkedin.com/company/aspargo-laboratories-inc/
Website https://aspargolabs.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Human + AI Synergy: Pleio combines emotionally aware AI with peer-to-patient support to boost medication adherence.
• Overcoming Emotional Barriers: Emotions like fear, loneliness, and stigma are major challenges after diagnosis.
• Real-World Impact: Pleio's approach improved adherence rates by up to 28% in GLP-1 medication trials.
• Ethical AI in Healthcare: Patient data is de-identified and overseen by a medical board to ensure ethical use.
• Laser Focus on Loneliness: Pleio’s next frontier is tackling loneliness as a primary emotional barrier in healthcare.

To Learn More About Our Guest And Their Company:
Guest LinkedIn https://www.linkedin.com/in/michaeloleksiw/
Company LinkedIn https://www.linkedin.com/company/pleio-inc/
Website http://www.pleio.com

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Innovative Imaging for Surgery – On Target Laboratories enables surgeons to see cancer at the cellular level using near-infrared imaging.
• Cytalux for Lung & Ovarian Cancer – Their FDA-approved drug, Cytalux, helps identify tumors in real-time, improving surgical outcomes.
• Surgeon-Driven Development – Continuous feedback from surgeons drives research, refining the technology for broader applications.
• Future of Cancer Surgery – With ongoing clinical trials, On Target Laboratories aims to expand its imaging technology to new indications.
• Industry Engagement – The company actively participates in key medical conferences, connecting with experts to advance cancer care.

To Learn More About Our Guest And Their Company:
Guest LinkedIn https://www.linkedin.com/in/bill-peters-749a332a/
Company LinkedIn https://www.linkedin.com/company/on-target-laboratories-inc/
Website http://www.ontargetlabs.com

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Company Focus: Arcutis Biotherapeutics, under Frank Watanabe, is dedicated to treating inflammatory skin conditions, with three FDA-approved products and a fourth pending.
• Significant Milestones: This year, Arcutis launched two new products and partnered with a primary care company to expand its reach.
• Patient-Centric Approach: Arcutis prioritizes patient needs by involving dermatology practitioners and patient insights directly in decision-making.
• Technological Perspective: While acknowledging AI's potential in drug discovery, Arcutis is focused on tangible, current advancements without prematurely implementing AI.
• Expanding Accessibility: Arcutis is actively working to extend its treatments to Medicare and Medicaid markets to support a broader patient demographic.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/frank-watanabe-419711/
Company LinkedIn https://www.linkedin.com/company/arcutis-inc/
Website https://www.arcutis.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Causal AI Explained: Aaron Mackey from Lokavant and Jonathan Crowther from Pfizer discuss the capabilities of causal AI in differentiating cause and effect in clinical trials.
• Comparison to Generative AI: The episode breaks down the distinctions between generative AI and causal AI, highlighting the advantages of causal approaches in clinical operations.
• Impact on Clinical Trial Feasibility: The experts explain how causal AI optimizes trial feasibility assessments, leading to more efficient and effective clinical processes.
• Forecasting Clinical Trials with AI: Insight into how causal AI improves data-driven decision-making and addresses the limitations of traditional trial forecasts.

To learn more about our guests and their companies:
Aaron's LinkedIn https://www.linkedin.com/in/aaronmackey/
Jonathan's LinkedIn https://www.linkedin.com/in/crowtherjonathan/

Lokavant LinkedIn https://www.linkedin.com/company/lokavant/
Pfizer LinkedIn https://www.linkedin.com/company/pfizer/

Lokavant Website https://www.lokavant.com/en-us/
Pfizer Website https://www.pfizer.com/

Our sponsor for this episode is:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Joerg Ahlgrimm discusses his journey in the pharmaceutical industry and his role at SK Pharmteco.
• The strategic integration of companies under SK Pharmteco to enhance global CDMO capabilities.
• The importance of a patient-centric approach in driving company success and innovation.
• Challenges and strategies for ensuring operational efficiency and overcoming funding difficulties in biotech.
• Ahlgrimm’s advice for emerging leaders on career growth and maintaining a patient-first focus.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/joerg-ahlgrimm-315a925/
Company LinkedIn https://www.linkedin.com/company/skpharmteco/
Website https://www.skpharmteco.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Elliot Green's transition from Oscar Health to founding Dandelion Health.
• Dandelion Health's innovative approach to real-world data and clinical AI.
• The importance of longitudinal data in advancing precision medicine.
• The potential of AI to accelerate drug development and improve healthcare outcomes.
• Upcoming events where Dandelion Health will share their advancements.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/elliott-green-98433b2/
Company LinkedIn https://www.linkedin.com/company/dandelion-health-ai/
Website https://dandelionhealth.ai/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Nicole Paulk's early inspiration in gene therapy during her PhD at OHSU.
• The transition from academia to entrepreneurship amid COVID-19.
• Siren Biotechnology's innovative approach with AAV immunogene therapy.
• The challenges and successes in securing funding and navigating regulatory landscapes.
• The exciting transition of Siren Biotechnology from preclinical to clinical trials.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/nicolepaulk/
Company LinkedIn https://www.linkedin.com/company/siren-biotechnology-inc/
Website https://sirenbiotechnology.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Sam Cooper shares his journey from Imperial College London to founding Phenomic.
• Phenomic's innovative approach combines AI with biological research.
• The company focuses on developing drugs targeting the tumor stroma.
• Phenomic's partnership with TileDB and Boehringer Ingelheim.
• Advice for budding biotech entrepreneurs from Sam Cooper.

To Learn More About Our Guests and their Companies:
LinkedIn https://www.linkedin.com/in/sam-cooper-537814134/
Company LinkedIn https://www.linkedin.com/company/phenomic/
Website https://phenomic.ai/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Rohit Nambisan discusses Lokavant's approach to leveraging AI in clinical trial feasibility.
• Christine Senn highlights the importance of thorough feasibility processes in rare disease trials.
• The need for diverse site participation and data inputs to improve trial accuracy and efficiency.
• The role of AI and technology in enhancing clinical trial processes.

To learn more about our guests and their companies:
Christine's LinkedIn https://www.linkedin.com/in/christinesenn/
Rohit's LinkedIn https://www.linkedin.com/in/rohitnambisan/

Advarra LinkedIn https://www.linkedin.com/company/advarra/
Lokavant LinkedIn https://www.linkedin.com/company/lokavant/

Advarra Website https://www.advarra.com/
Lokavant Website https://www.lokavant.com/en-us/

Our sponsor for this episode is:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Revolutionizing Treatments: Dr. Sam Clark discusses Terran Biosciences' mission to innovate treatments for neurological and psychiatric conditions.
• Innovative Drug Development: The company focuses on creating new mechanisms for treating depression, bipolar disorder, and schizophrenia.
• Smaller, Agile Teams: Terran Biosciences operates with a flat structure, utilizing highly trained experts to solve complex problems.
• Addressing Patent Monopolies: The company aims to break patent monopolies in pharma through innovative approaches and pro-drug strategies.
• Exciting Developments: Dr. Clark teases upcoming announcements, including long-acting and improved drug forms.

To learn more about our guests and their companies:
LinkedIn https://www.linkedin.com/in/sam-clark-md-phd-133139199/
Company LinkedIn https://www.linkedin.com/company/terran/
Website https://terranbiosciences.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Dr. Michael Kyle's Background: Insights into his journey from medical practice to becoming SVP & Chief Medical Officer of Currax Pharmaceuticals.
• Understanding Obesity: A discussion on different types of obesity and the importance of tailored treatments.
• Global Perspectives: Comparing how the U.S. and European countries handle obesity and the lessons to be learned.
• Evolving Treatments: The parallel evolution of hypertension and obesity treatments.
• Behavioral Approaches: The importance of sustainable lifestyle changes and behavior modification in addressing obesity.

To learn more about our guests and their companies:
LinkedIn https://www.linkedin.com/in/michael-l-kyle/
Company LinkedIn https://www.linkedin.com/company/currax-pharmaceuticals-llc/
Website https://www.curraxpharma.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Introduction of Colin Weller: Vice President and GM of Evidence Platform at Medable, Colin Weller discusses his role in advancing clinical research technology to streamline drug approvals.
• Challenges in Drug Development: Weller details the stagnant pace of drug development, highlighting the industry's need for innovation to improve efficiency and reduce costs.
• Medable's Ambitious Goals: Aiming to increase the number of drugs approved annually by tenfold through advanced SAS technology and AI, setting a new industry standard.
• Innovations in Clinical Trials: Medable has already cut study startup times by 50%, utilizing AI and automation to overhaul traditional processes.
• Future of Digital Clinical Trials: Weller predicts significant advancements in decentralized and digital trials, enhancing patient accessibility and data quality.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/colin-weller-294ab58/
Company LinkedIn: https://www.linkedin.com/company/medable-inc-/
Website: https://www.medable.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Stella Vnook, CEO of Likarda, discusses her transition from a science background to the business side of biotech and her journey to becoming CEO.
• Likarda specializes in core-shell spherification, creating beads with cells for targeted drug delivery, improving viability and efficacy.
• The company aims to enhance cell therapies, especially in liver cells and hormone therapy, and simplify cell transport logistics.
• Likarda's future goals include launching off-the-shelf products for osteoarthritis and advancing partnerships in cell therapy and regenerative medicine.
• Funding strategies and future plans involve a Series A funding round, non-dilutive funding, and efficient use of resources to scale up and innovate.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/vnook/
Company LinkedIn: https://www.linkedin.com/company/likarda-llc/
Website: https://likarda.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Samantha Dale Strasser, co-founder and Chief Science Officer of Pepper Bio, shares her transition from academia to entrepreneurship, driven by a personal mission to change healthcare outcomes.
• Pepper Bio, located in Boston, leverages transomics to integrate multiple data sets for precision medicine, aiming to treat diseases that are currently untreatable.
• Strasser’s focus is on developing treatments for challenging diseases, with an emphasis on oncology, inflammatory diseases, and neurodegenerative disorders.
• Pepper Bio’s approach in drug discovery combines its own pipeline development with strategic partnerships, speeding up the process of bringing new treatments to the clinic.
• The company has made significant strides in identifying novel targets and shelved assets, leading to a high success rate in in vivo model validations.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/samantha-dale-strasser/
Company LinkedIn: https://www.linkedin.com/company/pepperbio/
Website: https://pepper.bio/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Meet Cary Claiborne: Discover the visionary CEO behind Adial Pharmaceuticals.
• Understanding AD04: Dive into the science of this promising new treatment for alcohol use disorder.
• The Impact of Alcohol Use Disorder: A closer look at the challenges and the need for better treatments.
• A Glimpse into the Future: Explore how AD04 could revolutionize addiction treatment beyond alcohol use disorder.
• Adial's Mission and Vision: Hear directly from Claiborne about the company's path forward and commitment to innovation.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/cary-claiborne-sr-84a2217/
Company LinkedIn: https://www.linkedin.com/company/adialpharma/
Website: https://www.adial.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Discussion on innovative CNS drug development on BioBreakthroughs podcast.
• Learn about Praxis' genetics-inspired approach to tackling complex brain diseases.
• Souza highlights the challenges and opportunities in CNS treatment, including the impactful EMBOLD and EMBRAVE studies.
• Discover Praxis Precision Medicines' future prospects and their commitment to revolutionizing patient care in the CNS field.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/marcio-souza-2b02837/
Company LinkedIn: https://www.linkedin.com/company/praxis-precision-medicines-inc/
Website: https://praxismedicines.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Reed shares his 40-year journey in microbiology and immunology.
• Discussion on HDT Bio's approach to vaccine development for infectious diseases and cancer.
• Insight into the Amplify vaccine platform and its impact on global health.
• Reed's perspective on vaccine accessibility and affordability.
• Preview of HDT Bio's upcoming projects in oncology.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/steven-reed-b23b159b/
Company LinkedIn: https://www.linkedin.com/company/hdt-bio/
Website: https://www.hdt.bio/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Discussing the challenges in clinical research and strategies for overcoming them.
• Exploring the role of technology in modern clinical trials.
• Advarra's innovative approach to streamlining clinical research processes.
• Insights on the future of clinical trials and healthcare innovation.
• Key takeaways from the discussion and implications for the industry.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/gadi-saarony/
Company LinkedIn: https://www.linkedin.com/company/advarra/
Website: https://www.advarra.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Insightful discussion on innovative blood testing technology.
• Stein's journey in the healthcare and medtech sectors.
• Challenges and triumphs in developing new blood testing methods.
• Future prospects and impact of Babson Diagnostics in healthcare.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/david-stein-ceo/
Company LinkedIn: https://www.linkedin.com/company/babsondx/about/
Website: https://www.babsondx.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• The vision and strategies behind the Launchpad
• Houston as a key location for medical innovation
• Impact on the local and national biotech scene
• Upcoming projects and future prospects in biotechnology

To learn more about our guests and their companies:
Omid's LinkedIn: https://www.linkedin.com/in/omid-veiseh-0a545b3/
Paul's LinkedIn: https://www.linkedin.com/in/pcherukuri/
Website: https://www.rice.edu/
Company LinkedIn: https://www.linkedin.com/school/riceuniversity/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• The shift towards decentralized clinical trials.
• The impact of wearable technology on health monitoring.
• The role of patient-mediated Electronic Health Records (EHRs).
• Exploration of AI, wearables, and patient-centric data strategies.
• Katie Baca-Motes shares her perspectives on the advancements in digital healthcare.

To learn more about Katie and Scripps Research and Digital Trials and Engagement:
Guest LinkedIn: https://www.linkedin.com/in/katiebaca/
Website: https://digitaltrials.scripps.edu/
Company LinkedIn: https://www.linkedin.com/school/the-scripps-research-institute/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Discussing LUMRYZ, a new narcolepsy drug.
• Insights into the challenges of narcolepsy treatment.
• Avadel's future plans in healthcare innovation.

To learn more about Greg and Avadel Pharmaceuticals:
Guest LinkedIn: https://www.linkedin.com/in/greg-divis-a525334/
Website: https://www.avadel.com/
Company LinkedIn: https://www.linkedin.com/company/avadelpharmaceuticals/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

What you'll get out of this episode:

• Dr. Shankar Musunuri of Ocugen discusses gene and cell therapy innovations
• Focus on tackling unmet needs in ophthalmology and vaccine development
• Insights into Ocugen's unique platforms and global health impact
• Future prospects in biotech and healthcare advancements

To learn more about Ocugen:
Website: https://www.ocugen.com/
LinkedIn: https://www.linkedin.com/company/ocugen/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

• Discussing breakthroughs in healthcare diagnostics
• Insights on integrating technology in healthcare
• Truvian's mission: accessible and affordable healthcare
• Focus on early detection and intervention in medical testing
• Future vision for healthcare accessibility and efficiency

To learn more about Truvian: https://truvianhealth.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

• Mowery's progression from the chemical industry to biopharma leadership.
• Exploration of Mowery's experiences in the industry.
• KBI BioPharma: Insights into the company's impact and role in the biopharmaceutical industry.
• Discussion on KBI BioPharma's international facilities and outreach.
• Mowery shares his strategic vision for KBI BioPharma and the evolving CDMO industry.
• A focus on the importance of customer relationships and collaborative approaches in biopharma.
• Mowery's thoughts on the future of biopharma and leadership.

To learn more about KBI Biopharma: https://www.kbibiopharma.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

• Learn how AI optimizes clinical trial design and patient recruitment
• Explore the impact of AI on reducing drug development costs and timelines
• Understand the advancements toward personalized medicine
• Dive into the challenges and opportunities of adopting AI in life sciences
• Get insights on how other industries have successfully integrated AI and what healthcare can learn from them

To learn more about eClinical Solutions: https://www.eclinicalsol.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

• Understanding DEI: Diversity, Equity, and Inclusion explained
•  Cultivating Inclusion: Building trust and embracing inclusive behaviors
• Collaborative Success: How collaboration fuels progress
• Staying Informed: The importance of keeping up with DEI trends and legal developments
• Future of DEI: Boehringer Ingelheim's vision for a more inclusive future

To learn more about Boehringer Ingelheim: http://www.boehringer-ingelheim.com

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

• Journey from biochemistry to sell-side biotech business development.
• Current treatment landscape for ACI and the limitations therein.
• Introduction to ANEB-001, a promising antidote aimed at the CB1 receptor to counter cannabinoid overload.
• Impact of synthetic cannabinoids and the silent peril they pose.
• Upcoming milestones: Finalization of Phase 2 data and optimistic outlook towards FDA outcomes.

*Since the recording of this episode Simon has moved onto new endeavors*

To learn more about Anebulo Pharmaceuticals: https://www.anebulo.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

• Introduction to Dr. Helen Torley, CEO and president of Halozyme.
• Halozyme's mission to reduce treatment burdens for patients.
• The revolutionary Enhanze technology: Transforming IV infusions to subcutaneous injections.
• The significant impact of Halozyme's innovations on healthcare systems.
• The power of partnerships in driving Halozyme's success.

To learn more about Halozyme: https://halozyme.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

#Halozyme #InnovationInHealthcare #DrugDelivery #BioBreakthroughs #PatientCare

What you'll get out of this episode:

• Exploring Dr. Cruz's background in FDA and her transition to the private sector.
• Overview of Empatica: Foundation, mission, and their cutting-edge Health Monitoring Platform.
• The value of digital biomarkers in research.
• Advancements in remote patient monitoring and its significance in decentralized clinical trials.
• How Empatica ensures data protection and patient safety during clinical trials.
• A sneak peek into what's next for Empatica: Actigraphy mode and more!
• Closing thoughts and looking forward to future discussions.

To learn more about Empatica: https://www.empatica.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

#DigitalHealth #Empatica #PatientMonitoring #ClinicalTrials #HealthTech #BioBreakthroughs

What you'll get out of this episode:

• Raquel's academic background & introduction to drug development.
• The inspiration drawn from personal experiences and influential figures in the biotech industry.
• Challenges of co-founding multiple companies.
• The innovation behind Vincerx Pharma.
• The potential of antibody drug conjugates in modern medicine.
• Insights into Vincerx's upcoming ADC VIP 943.
• The vision and goals for Vincerx in the coming years.
• Key learnings Raquel has drawn from her vast experience in the biotech world.

To learn more about Vincerx Pharma Inc: https://vincerx.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

• Dive deep into the world of Congenital Adrenal Hyperplasia (CAH) treatments and drug development.
• Understand the challenges and rewards of addressing rare diseases, especially in pediatrics.
• Javier Szwarcberg discusses Spruce's innovative Tildesophon and its potential impact on the CAH therapeutic landscape.
• Discover the upcoming clinical updates from Spruce Biosciences and the promising future outlook for CH treatments.

To learn more about Spruce Biosciences: https://sprucebio.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

• Harvard MD/PhD, former physician, current CEO focusing on personalized medicine.
• Biological Dynamics Overview: 10-year-old company, isolates plasma particles from minimal blood samples for diagnostics.
• Aiming for early-stage detection of pancreatic cancer to improve survival rates.
• Their unique approach to target exosomes instead of DNA/RNA for richer data; aims to replace invasive tests.
• Expanding technology to other cancers and potentially Alzheimer's; involved in clinical trials.

To learn more about Biolgical Dynamics: https://biologicaldynamics.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

What you'll get out of this episode:

- Simon Arkell, CEO of Synthetica Bio, sheds light on biopharma's future
- Originally an Australian athlete, Arkell became a U.S.-based entrepreneur, focusing on machine learning, data analytics, and patient care.
- His standout contribution was through DeepLens in precision oncology.
- Synthetica Bio aims to provide advanced data solutions in biopharma using generative AI, addressing the industry's data analysis challenges.
- Despite abundant data, biopharma grapples with analysis bottlenecks due to task-specific traditional models.
- Synthetica Bio differentiates itself with versatile data interpretation using generative AI and a unique cloud-based microservices architecture.
- With backing from major venture capitalists and strategic partnerships, Synthetica Bio is on track for significant industry innovation.
- Overall, Synthetica Bio is driving transformation in biopharma, maximizing generative AI's potential.

To learn more about Synthetica Bio: https://syntheticabio.ai/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

What you'll get out of this episode:

- Ravi Samavedam of Azzur Group discusses lab space solutions for biotech.
- Azzur Group's clean rooms on demand address lab space shortages, offering flexible configurations.
- Their model eases GMP compliance burden by managing facilities and support services.
- Azzur Group accelerates therapies, focusing on cell and gene therapy innovation.
- Expansion plans aim to amplify their impact in the industry.

To learn more about Azzur Group: https://azzur.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

What you'll get out of this episode:

- Backstory on Pascal
- Leading CAR-T at Novartis and Atara, focusing on lymphoma.
- Creation of EBV T Cell Platform for cancer and autoimmune diseases.
- The milestones for Ebalo, including European approval.
- Impacting cell therapy with validation, quality manufacturing.
- Planned future directions, including FDA alignment and partnerships.

To learn more about Atara Biotherapeutics: https://www.atarabio.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

What you'll get out of this episode:

- Jason’s path to founding CTMC
- An overview of CTMC
- CTMC’s mission
- CTMC’s unique partnership with MD Anderson
- The exciting opportunities at CTMC
- CTMC’s mission to help patients & advancing novel scientific breakthroughs into medicines to ultimately end cancer
- The future of CTMC & the industry

To learn more about CTMC+: https://ctmc.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

What you'll get out of this episode:

• Pete's background
• Overview of FibroBiologics
• Their fibroblast technology platform and its therapeutic potential
• What his formula has been for growing and scaling the team and product pipeline
• Key takeaways from #BIO2023
• What trends do he sees developing right now in regenerative medicine that will continue through the end of 2023
• What's next?

To learn more about FibroBiologics: https://fibrobiologics.com/

Full Episode and more info here: https://sliceofhealthcare.com/10-pete-oheeron-chairman-ceo-founder-fibrobiologics/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

What you'll get out of this episode:

• Can you tell us about your background and what led you to LEXEO?
• What product candidates are development at LEXEO?
• How is what LEXEO is developing different than the current treatments in the neurological and cardiac spaces?
• At BIO you spoke to the topic of accelerated approval, can you provide some perspective on the pathways needed for accelerated approval in gene therapy?
• How does gene therapy address patient needs across disease areas?
• What's next?

Full Video and more info click here: Slice Of Healthcare Website

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

To learn more about LEXEO Therapeutics please use the links below:
- LEXEO TX LinkedIN - LEXEO TX Website -

What you'll get out of this episode:

- Sandra's background

- Overview of Debiopharm

- Tell us about Debiopharm’s approach to drug development. How does it work with startups to enhance innovation and expedite clinical trial timelines?

- What steps can companies take to improve patient quality of life in drug development?

- As the world continues to face a global drug shortage, how does Debiopharm bridge the gap between disruptive research and real-world application to ensure patients receive the life-saving drugs they need?

- What’s next for the future of biopharma?

To learn more about Debiopharm: https://www.debiopharm.com/

Full Episode and more info here: https://loom.ly/dkKu8RA

Our sponsors for this episode are: 
Sage Growth Partners https://www.sage-growth.com
FlipMD by GoodRX https://www.goodrx.com/
Quantum Health https://quantum-health.com/

We had the pleasure of hosting David Esposito, a visionary leader in the field of biotechnology as the President and CEO of ONL Therapeutics. Join us as we dive deep into the fascinating world of retinal diseases and explore the future of biotech!

In this episode, we covered:

- David's inspiring background and journey to becoming a leader in the industry

- An insightful overview of ONL Therapeutics and their groundbreaking work in the field of retinal diseases.

- The evolving landscape of retinal disease treatment and the remarkable progress made over the years.

- The role of artificial intelligence and machine learning in shaping the future of biotechnology.

- What's next for ONL Therapeutics?

We'd like to thank our sponsors for this episode, Sage Growth Partners, a leading healthcare consultancy, their support enables us to bring you thought-provoking discussions with industry experts. For more information, please go to www.sage-growth.com. 

Learn more about ONL Therapeutics follow these links: 

LinkedIn - Website

Also, be sure to follow Slice of Healthcare on our social channels:

Website  - LinkedIn - Twitter - YouTube - Newsletter

Don't miss out! Subscribe to our YouTube channel to catch all the engaging episodes and stay up-to-date with the latest advancements in biotech: https://www.youtube.com/@UCPuxsHtzFktm1XezuJp-KoA

What you'll get out of this episode:

• Richard's background
• Overview of Immunexpress
• The impact of a lack of reliable sepsis diagnostics
• SeptiCyte technology
• What's next?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

Learn more about Immunexpress follow these links: 

LinkedIn - Website 

Also, be sure to follow Slice of Healthcare on our social channels:

Website  - LinkedIn - Twitter - YouTube - Newsletter

What you'll get out of this episode:

• Rohit's background
• Overview of Lokavant
• The biggest data challenges in clinical trials today
• It's mentioned that late-phase trials are now generating 3x more data than 10 years ago. How is Lokavant managing this influx of data?
• The limitations of legacy systems and processes in handling the data from clinical trials
• How Lokavant's approach differs
• What's next?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

What you'll get out of this episode:

• Joel's background
• Curavit Overview
• CRO and virtual clinical site services for clinical trials
• Traditional vs. Decentralized Clinical Trials
• What the future of this space looks like?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

What you'll get out of this episode:

• Bahl's background
• Overview of AI Proteins
• How they are utilizing computational protein design to engineer synthetic miniproteins therapeutics that can bind to any target
• The process and challenges
• Key differentiators
• Their impact on the future of medicine

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

What you'll get out of this episode:

• Rombotis's background and an overview of Cyclacel
• Which part of the cell cycle they're targeting?
• What their leading candidates are, and the current clinical trial statuses of each.
• What makes their CDK inhibitor strategy unique compared to other biopharmaceutical companies?
• Their PLK1 program
• Near-term milestones and what's next?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners

What you'll get out of this episode:

• Kendalle's career journey
• Workforce training program
• ResearcHERS
• Trends to watch

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners